Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 242-582-0
CAS number: 18794-84-8
Table 1: Physical signs of postnatal
development of offspring of rats treated orally with β-myrcene (0,
100, 300 and 500 mg/kg bw/day)
Primary coat (%)
Incisor eruption (%)
Eye opening (%)
* P < 0.05 compared to controls (chi-square test).
A study was conducted to investigate the effects of
β-myrcene on fertility and general reproductive performance in
Wistar rats similarly to OECD Guideline 415.
β-Myrcene (0, 100, 300 and 500 mg/kg bw/day) in peanut oil
was administered daily by gavage to male Wistar rats (15/group)
for 91 days prior to mating and during the mating period, as well
as to females (45/group) continuously for 21 days before mating,
during mating and pregnancy, and throughout the period of
lactation up to postnatal Day 21. All Fo-males and -females were
evaluated for weight development, mortality and signs of toxicity.
Pregnant females were observed for weight gain, signs of abortion,
dystocia and prolonged duration of pregnancy. Parameters examined
in all male parental generations include testis weight, sperm
count in testes and cauda epididymis. On Day 21 of pregnancy
one-third of the females of each group were submitted to cesarean
section. Resorption, implantation, as well as dead and live
fetuses were counted. All fetuses were examined for external
malformations, weighed and examined for skeleton evaluation. The
remaining dams were allowed to give birth to their offspring. The
progeny was examined at birth and subsequently up to postnatal Day
21. Mortality, weight gain and physical signs of postnatal
development were evaluated.
An increase in liver and kidney weights were observed
in male and female rats at 500 mg/kg bw/day but in the
absence of associated pathology. No other sign of toxicity
was noted in parental male and female rats exposed to
β-myrcene. The test material did not affect the mating index
or the pregnancy index. No sign of maternal toxicity and no
increase in externally visible malformations were observed
at any dose level. At the highest dose tested (500 mg/kg
bw/day) there was a slight increase in resorption rate (3% v
5% in controls) and a higher frequency of fetal skeleton
anomalies were reported. The latter was not considered to be
treatment related but were attributed to an increase in
spontaneous strain-specific findings. No adverse effect on
postnatal weight gain was noted but days of appearance of
primary coat, incisor eruption and eye opening were reported
to be slightly delayed in exposed offspring; these minor
developmental findings were however not dose related and it
is questionable if they were related to treatment.
In conclusion, the no-observed-adverse-effect level
(NOAEL) for toxic effects on fertility and general
reproductive performance of β-myrcene by the oral route was
reported to be 300 mg/kg bw/day in Wistar rats.
The findings were not however clearly treatment
or dose related, hence 300 mg/kg/day is probably a
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again